2021 Approvals Expand Access to Care for Patients Across Tumor Types
February 4th 2022
In 2021, 13 novel agents were approved across hematology/oncology. Additionally, there were many other notable approvals—whether they were new formulations, expanded indications, or biosimilar approvals—across tumor types that expanded accessibility for varying patient populations.